|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM353106305 |
| 003 |
DE-627 |
| 005 |
20250304104751.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2023.109264
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1176.xml
|
| 035 |
|
|
|a (DE-627)NLM353106305
|
| 035 |
|
|
|a (NLM)36804225
|
| 035 |
|
|
|a (PII)S1521-6616(23)00043-8
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Scherlinger, Marc
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Chronic stimulation with SARS-CoV-2 spike protein does not trigger autoimmunity
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 14.03.2023
|
| 500 |
|
|
|a Date Revised 18.03.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2023 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Autoimmune manifestations were reported in people infected with SARS-CoV-2. Repetitive exposure of mice to foreign antigen may lead to the onset of autoimmunity. We therefore investigated whether repetitive exposure to the SARS-CoV-2 spike protein could result in autoimmunity. To address this hypothesis, we repeatedly immunized C57Bl/6 mice with spike protein injected intraperitoneally. At the end of the immunization, mice which received spike protein produced anti-spike IgG but none of them developed anti-dsDNA antibodies or proteinuria. In conclusion, repetitive immunization with SARS-CoV-2 spike protein does not induce autoimmunity in the present mice model. Albeit reassuring, these results need to be confirmed by large epidemiological study evaluating the incidence of autoimmune diseases in individuals with repetitive SARS-CoV-2 antigen exposure
|
| 650 |
|
4 |
|a Letter
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Autoimmunity
|
| 650 |
|
4 |
|a C57Bl/6
|
| 650 |
|
4 |
|a SARS-CoV-2
|
| 650 |
|
4 |
|a Systemic lupus
|
| 650 |
|
7 |
|a spike protein, SARS-CoV-2
|2 NLM
|
| 650 |
|
7 |
|a Spike Glycoprotein, Coronavirus
|2 NLM
|
| 650 |
|
7 |
|a Antibodies, Viral
|2 NLM
|
| 700 |
1 |
|
|a Sibilia, Jean
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tsokos, George C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gottenberg, Jacques-Eric
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 248(2023) vom: 08. März, Seite 109264
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:248
|g year:2023
|g day:08
|g month:03
|g pages:109264
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2023.109264
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 248
|j 2023
|b 08
|c 03
|h 109264
|